Agoracom Blog Home

Posts Tagged ‘CBD’

Marijuana Company of America $MCOA Completes Financing for Cultivation Facility in Washington State $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:51 AM on Thursday, November 9th, 2017

15233 mcoa

  • Completed its financing of $800,000 in cash and 15 million shares of the Company’s common stock in full satisfaction of the amended terms of the joint venture agreement with Bougainville Ventures, Inc
  • Company has secured a 50% equity stake in BV-MCOA Management, LLC and will receive 50% of the net profits from leasing the facility, which will accommodate a contracted cannabis production and processing tenant with an approved Tier 3, I-502 license

Escondido, California–(November 9, 2017) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that it has completed its financing of $800,000 in cash and 15 million shares of the Company’s common stock in full satisfaction of the amended terms of the joint venture agreement with Bougainville Ventures, Inc. (“BV”).

Per the terms of the agreement and the completion of funding, the Company has secured a 50% equity stake in BV-MCOA Management, LLC and will receive 50% of the net profits from leasing the facility, which will accommodate a contracted cannabis production and processing tenant with an approved Tier 3, I-502 license. As turnkey landlords, MCOA and BV look to provide an ideal cultivation environment for their future tenant and it is anticipated that construction of the greenhouse will be completed in Q1 2018.

On November 1, 2017, the Company entered into a second Securities Purchase Agreement with St. George. The Secured Convertible Promissory Note has a principal amount of $601,420.00 with the right to purchase at any time on or after November 1, 2017, until November 1, 2022, twenty-two million (22,000,000) shares of Company’s common stock.

Donald Steinberg, MCOA CEO said, “We are pleased to complete funding for this joint venture and we are looking forward to the beginning of the construction of the greenhouses. As more states, most notably California in 2018, legalize recreational cannabis, MCOA is exploring opportunities to replicate this business model and develop our real estate portfolio.”

This joint venture project is solely for the purpose of cultivation and processing of legal marijuana within the State of Washington only and not beyond its borders. The Company will lease the turnkey property to the licensed tenant, thus acting solely as a landlord.

The original terms of the JV agreement with BV called for MCOA to fund $1,050,000 in cash. Both parties agreed to reduce the cash amount to $800,000 and issue 15 million shares of restricted common stock on November 7, 2017.

About Bougainville Ventures, Inc.

Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on marijuana. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to licensed I-502 tenant-growers and luxury crop growers who will lease the facilities for production and processing. Bougainville does not “touch the plant” and only provides growing infrastructure as a landlord for licensed marijuana growers in the state of Washington. Bougainville has a strong management team with relevant experience and education in place with a focus on build-out and occupancy of its planned greenhouses in Oroville, WA. Strategic plans to expand its land bank, greenhouse campus and I-502 tenant-grower clients are scheduled for expanding operations.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWire/MCOA

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office

Editor@NetworkNewsWire.com

 

Tetra Bio-Pharma $TBP.ca Concludes its First Sale of Rx Princeps(TM) Inhalation Device

Posted by AGORACOM-JC at 8:16 AM on Thursday, November 9th, 2017

Tbp large new

  • Announced its first sale of its Rx Princeps™ inhalation device
  • Sale of this inhalation device is the first step towards the sale of Rx Princeps™. 

OTTAWA, ONTARIO–(Nov. 9, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced its first sale of its Rx Princeps™ inhalation device. The sale of this inhalation device is the first step towards the sale of Rx Princeps™.

“I am happy to announce the first batch order of our medical cannabis inhalation devices. This is the first step in generating a steady revenue stream and it is the beginning of a new phase in our development. Sales of Rx Princeps ™ inhalation device will be an additional revenue stream for Tetra. Our inhalation device is a unique, high quality, CSA-approved customized titanium pipe, designed by our partner, Ford Pharmacy. With this launch Tetra is providing a high quality, standardized treatment with clinical data to patients in need.” As Rx Princeps™ (dried cannabis) will soon be launched under ACMPR through Aphria, and we are expecting to generate around $1.5 millions in sales, in fiscal 2018. Through our promotion and education efforts in Quebec, New Brunswick and part of Ontario, we estimate that over eight thousand patients will start using Rx Princeps™ under prescription from their doctors over in the next twelve months.” states Bernard Fortier, CEO of Tetra.

Mr Fortier highlights that “It is important to consider that only 4 % of physicians today consider prescribing cannabis. A fixed-dose approach, as we are promoting based on our original clinical data, is attractive to doctors because the treatment dose is standardized. We have a huge opportunity in educating doctors on our clinical approach.”

Tetra has received its first sales order from Sante Cannabis. Sante Cannabis is the first cannabinoid clinic and medical marijuana resource centre in Quebec. Healthcare professionals from Sante Cannabis support patients in their medical journey with cannabis.

Rx Princeps™ allows patients to optimize the benefits of medical cannabis through the intake of a standardized amount of product. The Rx Princeps™ inhalation device is an essential accessory to ensure consistency of treatment, as well as optimize the potency of the product, while minimizing wastes for the patient.

200,000 patients are already registered under the ACMPR program and around 1.5 million adults in Canada suffer from chronic pain and are considered non-responders to opioids; medical cannabis could be a therapeutic answer for those patients but physicians need bioavailability and safety data to prescribe medical cannabis with confidence. According to Health Canada, less than 3,000 physicians actually prescribe cannabis to their patients. Tetra is committed to provide them this data. Tetra has begun educating pain clinics and the medical profession across Canada on Rx Princeps™, including its advantages for patients. The Tetra medical team was at the Academic Pain Day hosted by the Ontario Pain Foundation this Wednesday to inform pain physicians about the benefits of Rx Princeps™. This was also an opportunity to introduce to them Tetra’s phase 1 data on its drug candidate PPP001.

Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now entering this lucrative market and plans on progressively grabbing a significant share of it over the next two years.

About Rx Princeps™:

Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps™ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001. Rx Princeps™ will be available across Canada, through Licensed Producer Aphria Inc., for patients who have a prescription from their physicians.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
anne-sophie.courtois@tetrabiopharma.com
(514) 360-8040 Ext. 210
www.tetrabiopharma.com

FEATURE: Tetra Bio-Pharma $TBP.ca – Only Pharma Company To Have Clinical Studies for Smoked #Marijuana #MMJ #CBD

Posted by AGORACOM-JC at 11:38 AM on Tuesday, October 24th, 2017

WHY TETRA BIO-PHARMA?

 

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected

Global Hemp Group $CHG.ca and Marijuana Company of America $MCOA to Enter Joint Venture Agreement with Space Cowboys’ Colorado Farm

Posted by AGORACOM-JC at 11:18 AM on Tuesday, October 10th, 2017

15233 mcoa

  • Marijuana Company of America Inc.  and Global Hemp Group  announce that they have jointly entered into a letter of intent with Space Cowboys, Inc. or the purposes of forming a joint venture
  • Space Cowboys is an existing fully licensed and compliant hemp-derived cannabinoid producer in Colorado

Escondido, California–(October 10, 2017) – Marijuana Company of America Inc. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, and Global Hemp Group (CSE: GHG) (FSE: GHG) (OTC Pink: GBHPF), (collectively the “Companies“), are pleased to announce that they have jointly entered into a letter of intent with Space Cowboys, Inc. (“Space Cowboys“) for the purposes of forming a joint venture (the “Joint Venture“). Space Cowboys is an existing fully licensed and compliant hemp-derived cannabinoid producer in Colorado.

Pursuant to the terms of the letter of intent and subject to the Companies obtaining sufficient financing, the Companies will invest US$2.5 Million in exchange for a 25% equity interest in Space Cowboys. The investment funds will be used to expand Space Cowboys’ cultivation operation.

Space Cowboys is in its fourth year of operation and is in full compliance with Colorado state law and the Colorado Department of Agriculture. The business consists of both indoor and outdoor cultivation of highly concentrated CBD hemp on properties located in Longmont and Loveland, Colorado. Space Cowboys’ current hemp crops will be harvested in the latter part of October and prepared for extraction of the high-value cannabinoids.

In addition to the potential revenue streams generated from Space Cowboys’ ongoing high cannabinoid hemp production, this Joint Venture will provide the opportunity to be a part of a legal operation with the extensive knowledge and experience required to cultivate and process industrial hemp into raw cannabinoids. For MCOA, it will also provide a consistent cannabinoid supply from a known source and trusted partner for its hempSMART™ product line. This will also enable Global Hemp Group to develop its Hemp Agro-Industrial Zone concept.

“MCOA has always been interested in developing hemp farms and processing here in the United States. By initiating this Joint Venture, the Company will accomplish this objective along with securing its supply chain of raw cannabinoids. It is an important step in the continued development of the hempSMART brand, which distributes a hemp-based Cannabinoid product line,” said CEO, Donald Steinberg.

The transaction is subject to a number of conditions, including but not limited to, completion of satisfactory due diligence, entry into a definitive agreement and receipt of any necessary regulatory approvals. There is no assurance such conditions will be met or that the Companies will be able to secure the financing necessary to complete the transaction on acceptable terms or at all.

About Space Cowboys

Space Cowboys operates hemp farms in the state of Colorado for the primary purpose of Cannabinoid production. Space Cowboys’ operations are in full compliance with Colorado state law and the Colorado Department of Agriculture.

About Global Hemp Group Inc.

Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp and cannabis, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and establish a greater collective valuation.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Email Contact

Invested in INSYS Therapeutics $INSY ? Tetra Bio-Pharma $TBP.ca is the Only pharmaceutical company to have clinical studies for smoked marijuana

Posted by AGORACOM-JC at 11:20 AM on Wednesday, October 4th, 2017

Tbp large new

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.

Tetra Bio-Pharma $TBP.ca to engage in co-development and distribution partnership with major healthcare specialty distributor

Posted by AGORACOM-JC at 8:19 AM on Wednesday, September 20th, 2017

Tbp large new

  • Announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry
  • Privately-owned partner has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals
  • First product will be launched in Q1 2018 with subsequent products already in development for the remainder of 2018
  • Tetra and its partner will be tapping into the overall Over-The-Counter topical analgesics market of more than $300 million in sales in Canada, with the US market reaching over $2.9 billion, according to an IMS analysis

OTTAWA, ONTARIO–(Sept. 20, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry.

This privately-owned partner, which asked to remain unnamed for the time being, has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals. Through their distribution channel, they have access to over 3000 specialized healthcare businesses in Canada and already work with a worldwide network of partners, including the USA.

Tetra and its partner are working together to develop a new line of products, leveraging Tetra’s clinical and product development expertise. The first product will be launched in Q1 2018 with subsequent products already in development for the remainder of 2018. Tetra and its partner will be tapping into the overall Over-The-Counter (OTC) topical analgesics market of more than $300 million in sales in Canada, with the US market reaching over $2.9 billion, according to an IMS analysis. Both companies are expecting to grab a share if the specialized OTC topical analgesics market in a short period of time and could see sales generated from this distribution channel reaching $3 million for Canada in the 1st year. Since the initial launch phase will be focused on the Canadian market, further guidance will be provided as Tetra’s partner gets ready to launch in the US.

« We’re excited to enter this specialized market as there is a significant need for our clinical expertise in product development. This partnership opens a new distribution channel for our pharmaceutical retail division not only in Canada, but also worldwide through their active partners in the US and Europe. Tetra remains committed and is actively developing partnerships to generate a significant revenue stream. This partnership demonstrates our team’s focus and dedication in accelerating our commercialization strategy towards selling a specialized line of products in our pharmaceutical retail business, » comments Bernard Fortier, CEO of Tetra Bio-Pharma.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra has three core expertise: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based drugs.

More information at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Anne-Sophie Courtois
Vice-President Marketing & Communication
1 (514) 360-8040 Ext. 210
Anne-sophie.courtois@tetrabiopharma.com
www.tetrabiopharma.com

Tetra Bio-Pharma $TBP.ca getting ready to file a clinical trial application to initiate phase 3 clinical trial on terminal cancer patients in the coming weeks

Posted by AGORACOM-JC at 8:17 AM on Monday, September 18th, 2017

Tbp large new

  • Announced that it will be filing a clinical trial application in the coming weeks to therapeutic products directorate 
  • Purpose to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients
  • With this filing, Tetra expects to be on time with its previously announced schedule with the development of PPP001

OTTAWA, ONTARIO–(Sept. 18, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announces that it will be filing a clinical trial application (CTA) in the coming weeks to therapeutic products directorate (TPD) to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients. With this filing, Tetra expects to be on time with its previously announced schedule with the development of PPP001. The corporation worked with physicians of Sante Cannabis to design a clinical trial that would demonstrate the safety and efficacy of PPP001 in terminal cancer patients. In addition, as part of the clinical trial, Tetra will collect the pharmacoeconomics evidence required from provincial insurers in order to support the reimbursement of the first cannabis prescription drug.

A significant percentage of patients placed on a cannabis treatment suffer from side effects that are not tolerable. This can lead to patients stopping a potentially effective therapy. As part of its early phase clinical research, Tetra developed dosing strategies to minimize moderate and severe side effects in patients. This dosing strategy was developed in healthy volunteers over the last few months and has shown to be effective in reducing the severity of the side effects and preventing certain serious ones. This allows TBP to initiate its Phase 3 trial based on clinical data proposing a more tolerable approach to consuming smoked cannabis and to assess PPP001 in terminal cancer patients. This is a significant step in the development of a safe, tolerable and effective new drug for the management of chronic pain in terminal cancer patients with co-morbidities.

This will be the first Phase 3 clinical trial studying the therapeutic benefits of a smoked dried cannabis prescription drug in terminal cancer patients. Due to the status of cannabis under the Controlled Drugs and Substances Act in Canada, over the last four months the corporation developed procedures and methods that would both satisfy the Narcotic Controls Regulations and ensure the protection of patients consuming the cannabis. The corporation is confident that these procedures will be well received by Health Canada as they ensure compliance with both the Food and Drug Act and Controlled Drugs and Substances Act.

Tetra also reports that it has restructured its investors and public relation functions to integrate them with the marketing and communication functions. Mr. Edward Miller is leaving the Corporation effective as of today. We want to thank Mr. Miller for the work he has done for the Corporation over the last months and wish him all the success he deserves for his new professional projects.

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra has three core expertise: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based drugs.

More information at: www.tetrabiopharma.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Source: Tetra Bio-Pharma

Tetra Bio-Pharma Inc.
Anne-Sophie Courtois
Vice- President Marketing & Communication
(514) 360 8040 Ext. 210
Anne-sophie.courtois@tetrabiopharma.com
www.tetrabiopharma.com

Marijuana Company of America $MCOA.us Announces #hempSMART 2.0 With New Website and Affiliate Program

Posted by AGORACOM-JC at 8:54 AM on Thursday, September 7th, 2017

15233 mcoa

  • Announced a major update of hempSMART™, the Company’s wellness focused Cannabidiol (CBD) marketing and distribution division
  • www.hempSmart.com and its network marketing platform have been completely redeveloped
  • Provides a more user friendly experience to its affiliates and customers

ESCONDIDO, CA–(Sep 7, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company“) (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution company, is pleased to announce a major update of hempSMART™, the Company’s wellness focused Cannabidiol (CBD) marketing and distribution division.

The hempSMART website: www.hempSmart.com and its network marketing platform have been completely redeveloped to provide a more user friendly experience to its affiliates and customers, and to also provide users with the comprehensive tools necessary to succeed in the growing $1.9 Trillion Wellness Industry.

The new website and network marketing platform have a significantly improved design, expanded content and a more user friendly e-commerce platform that offers the ability to easily expand due to the flexibility of the business platform it is built on. Affiliate’s will now experience a more effective, reliable and streamlined sales process to rapidly expand the Company’s consumer base and Affiliate success stories.

The new hempSMART Affiliate sales and distribution method is designed to ensure that our Affiliates play a leading role in the rapidly emerging Cannabidiol (CBD) movement within the Wellness Industry. The Company is in ongoing discussions about expanding internationally into multiple countries in 2018.

“The solid foundation that our new system and online platform offers will enable our Affiliates to fully utilize their abilities to grow their organizations in the U.S. and globally. Our team is in place, our products are being well received in the market, and we are in an industry that is experiencing exponential growth. We are building a strong foundation of technology, products and a strategic marketing plan that is designed to offer great benefits to our Affiliates who are the key to our success. We look forward to a robust and exciting time for our company,” said CEO, Donald Steinberg.

About Marijuana Company of America, Inc.

MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

FORWARD LOOKING STATEMENT
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

$MCOA recently announced $5 Million fixed funding commitment, Find out more #MMJ #Hemp #Marijuana

Posted by AGORACOM-JC at 3:15 PM on Thursday, August 24th, 2017

15233_mcoa

MCOA: OTC

RECENT EVENTS

  • Announced $5 Million Fixed Funding Commitment READ MORE
  • Company Announces the Filing of Form 10 Registration Statement with SEC READ MORE
  • Launch of New Website READ MORE
  • Company Invests in Global Payout’s MoneyTrac READ MORE
  • Announced Formation of Strategic Advisory Board READ MORE
  • Finalized Joint Venture Agreement With Bougainville Ventures in Washington State READ MORE 
  • Completed PCOAB Audit READ MORE

$MCOA.us At The Forefront of #Hemp Marketing and Distribution, Recently Announced $5 Million Fixed Funding Commitment

Posted by AGORACOM-JC at 9:25 AM on Tuesday, August 8th, 2017

15233_mcoa

MCOA: OTC

RECENT EVENTS

  • Announced a $5 Million Fixed Funding Commitment READ MORE
  • Company Announces the Filing of Form 10 Registration Statement with SEC READ MORE
  • Launch of New Website READ MORE
  • Company Invests in Global Payout’s MoneyTrac READ MORE
  • Announced Formation of Strategic Advisory Board READ MORE
  • Finalized Joint Venture Agreement With Bougainville Ventures in Washington State READ MORE
  • Completed PCOAB Audit READ MORE

BRANDS

MCOA is aggressively building a portfolio of investments and joint ventures that represent the highest integrity and professionalism in the legal cannabis markets.